Biogen Weighs Aduhelm Lessons Ahead Of Lecanemab Launch

 
• By Jessica Merrill

Plans for launching a second Alzheimer's drug, lecanemab, will be scaled back compared to Aduhelm, the firm predicted, though partner Eisai has not finalized Biogen's commercial role yet.

Studying
lessons learned from Aduhelm launch will inform lecanemab • Source: Shutterstock

More from Earnings

More from Business